242 related articles for article (PubMed ID: 32072779)
1. [Recent advances in the development of bispecific antibodies].
Ye J; Meng S; Zhu X
Sheng Wu Gong Cheng Xue Bao; 2020 Jan; 36(1):33-43. PubMed ID: 32072779
[TBL] [Abstract][Full Text] [Related]
2. Bispecific antibodies: design, therapy, perspectives.
Sedykh SE; Prinz VV; Buneva VN; Nevinsky GA
Drug Des Devel Ther; 2018; 12():195-208. PubMed ID: 29403265
[TBL] [Abstract][Full Text] [Related]
3. A review of bispecific antibodies and antibody constructs in oncology and clinical challenges.
Suurs FV; Lub-de Hooge MN; de Vries EGE; de Groot DJA
Pharmacol Ther; 2019 Sep; 201():103-119. PubMed ID: 31028837
[TBL] [Abstract][Full Text] [Related]
4. Bispecific monoclonal antibodies for targeted immunotherapy of solid tumors: Recent advances and clinical trials.
Hosseini SS; Khalili S; Baradaran B; Bidar N; Shahbazi MA; Mosafer J; Hashemzaei M; Mokhtarzadeh A; Hamblin MR
Int J Biol Macromol; 2021 Jan; 167():1030-1047. PubMed ID: 33197478
[TBL] [Abstract][Full Text] [Related]
5. Bispecific Antibodies: From Research to Clinical Application.
Ma J; Mo Y; Tang M; Shen J; Qi Y; Zhao W; Huang Y; Xu Y; Qian C
Front Immunol; 2021; 12():626616. PubMed ID: 34025638
[TBL] [Abstract][Full Text] [Related]
6. Immunotherapeutic progress and application of bispecific antibody in cancer.
Kang J; Sun T; Zhang Y
Front Immunol; 2022; 13():1020003. PubMed ID: 36341333
[TBL] [Abstract][Full Text] [Related]
7. Bispecific antibodies targeting immunomodulatory checkpoints for cancer therapy.
Zhang T; Lin Y; Gao Q
Cancer Biol Med; 2023 Mar; 20(3):181-95. PubMed ID: 36971124
[TBL] [Abstract][Full Text] [Related]
8. Bispecific antibodies: an innovative arsenal to hunt, grab and destroy cancer cells.
Grandjenette C; Dicato M; Diederich M
Curr Pharm Biotechnol; 2015; 16(8):670-83. PubMed ID: 25941884
[TBL] [Abstract][Full Text] [Related]
9. Bispecific antibodies and trispecific immunocytokines for targeting the immune system against cancer: preparing for the future.
Fournier P; Schirrmacher V
BioDrugs; 2013 Feb; 27(1):35-53. PubMed ID: 23329400
[TBL] [Abstract][Full Text] [Related]
10. Bioassay Development for Bispecific Antibodies-Challenges and Opportunities.
Register AC; Tarighat SS; Lee HY
Int J Mol Sci; 2021 May; 22(10):. PubMed ID: 34069573
[TBL] [Abstract][Full Text] [Related]
11. Bispecific antibodies.
Kontermann RE; Brinkmann U
Drug Discov Today; 2015 Jul; 20(7):838-47. PubMed ID: 25728220
[TBL] [Abstract][Full Text] [Related]
12. Bispecific antibodies: a mechanistic review of the pipeline.
Labrijn AF; Janmaat ML; Reichert JM; Parren PWHI
Nat Rev Drug Discov; 2019 Aug; 18(8):585-608. PubMed ID: 31175342
[TBL] [Abstract][Full Text] [Related]
13. Biology drives the discovery of bispecific antibodies as innovative therapeutics.
Nie S; Wang Z; Moscoso-Castro M; D'Souza P; Lei C; Xu J; Gu J
Antib Ther; 2020 Jan; 3(1):18-62. PubMed ID: 33928225
[TBL] [Abstract][Full Text] [Related]
14. Bispecific antibodies for targeted delivery of anti-cancer therapeutic agents: A review.
Beishenaliev A; Loke YL; Goh SJ; Geo HN; Mugila M; Misran M; Chung LY; Kiew LV; Roffler S; Teo YY
J Control Release; 2023 Jul; 359():268-286. PubMed ID: 37244297
[TBL] [Abstract][Full Text] [Related]
15. Bispecific antibodies in haematological malignancies.
Viardot A; Bargou R
Cancer Treat Rev; 2018 Apr; 65():87-95. PubMed ID: 29635163
[TBL] [Abstract][Full Text] [Related]
16. Bispecific Antibodies (bsAbs): Promising Immunotherapeutic Agents for Cancer Therapy.
Acheampong DO; Adokoh CK; Ampomah P; Agyirifor DS; Dadzie I; Ackah FA; Asiamah EA
Protein Pept Lett; 2017; 24(5):456-465. PubMed ID: 28117014
[TBL] [Abstract][Full Text] [Related]
17. Recent advances of bispecific antibodies in solid tumors.
Yu S; Li A; Liu Q; Yuan X; Xu H; Jiao D; Pestell RG; Han X; Wu K
J Hematol Oncol; 2017 Sep; 10(1):155. PubMed ID: 28931402
[TBL] [Abstract][Full Text] [Related]
18. Bispecific Antibody (bsAb) Construct Formats and their Application in Cancer Therapy.
Acheampong DO
Protein Pept Lett; 2019; 26(7):479-493. PubMed ID: 30864494
[TBL] [Abstract][Full Text] [Related]
19. Factors Affecting the Cancer Immunotherapeutic Efficacy of T Cell Bispecific Antibodies and Strategies for Improvement.
Long M; Mims AS; Li Z
Immunol Invest; 2022 Nov; 51(8):2176-2214. PubMed ID: 36259611
[TBL] [Abstract][Full Text] [Related]
20. "NextGen" Biologics: Bispecific Antibodies and Emerging Clinical Results.
Thakur A; Lum LG
Expert Opin Biol Ther; 2016; 16(5):675-88. PubMed ID: 26848610
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
